Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

Margaret R Hammerschlag, Tamara Reznik, Patricia M Roblin, Julio Ramirez, James Summersgill, Stanley Bukofzer

Journal: The Journal of antimicrobial chemotherapy 2003;51(4):1025-8

PMID: 12654764

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Nasopharyngeal specimens for culture of Chlamydia pneumoniae were obtained from patients with community-acquired pneumonia enrolled in a randomized study comparing the novel ketolide antibiotic ABT-773 at a dose of 150 mg once a day to 150 mg twice a day, by mouth for 10 days. C. pneumoniae was eradicated from the nasopharynx of 10 of 10 (100%) microbiologically evaluable patients. MICs and MBCs for 13 isolates of C. pneumoniae from 12 patients obtained before and after therapy were performed against ABT-773. The MIC90 and MBC90 of ABT-773 were 0.015 mg/L.

Address: Department of Pediatrics, State University of New York Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, New York, NY 11203-2098, USA. [email protected]

DOI: 10.1093/jac/dkg154

Link outs

Free resources

Medical:

https://medlineplus.gov/chlamydiainfections.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Aged, Chlamydia Infections, Chlamydophila pneumoniae, Double-Blind Method, Erythromycin, Female, Humans, Ketolides, Male, Microbial Sensitivity Tests, Middle Aged, Nasopharynx, Pneumonia, Bacterial, Reverse Transcriptase Polymerase Chain Reaction